Australia's most trusted
source of pharma news
Monday, 20 May 2024
Posted 8 March 2022 AM
The axe has fallen at Biogen with the company confirming job losses to the Australian team but keeping the exact number of layoffs confidential 'out of respect' for employees.
The company also remained tight-lipped on which positions had been slashed - although there is speculation over the team built around the controversial drug Alzheimer's drug Aduhelm, which is still under TGA review but has had poor sales overseas, following questions about its efficacy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.